Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05785767 · ClinicalTrials.gov registry record · Phase 2
A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Phase 2 study of Advanced Non-Small-Cell Lung Cancer, sponsored by Regeneron Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 850
- Enrollment target
- 20
- Study locations
NCT05785767: Active Phase 2 study of Advanced Non-Small-Cell Lung Cancer, sponsored by Regeneron Pharmaceuticals.
NCT05785767 is a Phase 2 study of Advanced Non-Small-Cell Lung Cancer that is active but no longer recruiting, run by Regeneron Pharmaceuticals. The registered enrollment target is 850 participants, above the 344-participant average among 22 other Advanced Non-Small-Cell Lung Cancer trials with a reported enrollment target (147% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05785767, a Phase 2 study of Advanced Non-Small-Cell Lung Cancer, is active but no longer recruiting, sponsored by Regeneron Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 850 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is researching an experimental drug called fianlimab (also called REGN3767), combined with a medication called cemiplimab (also called REGN2810), individually called a "study drug" or collectively called "study drugs". The study is focused on patients who have advanced non-small cell lung cancer (NSCLC). The aim of the study is to see how effective the combination of fianlimab and cemiplimab is in treating advanced NSCLC, in comparison with cemiplimab by itself. The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs * How much study drug is in your blood at different times * Whether the body makes antibodies against the study drugs (which could make the drug less effective or could lead to side effects) * How administering the study drugs might improve your quality of life
Primary Outcome
Proportion of patients with a best overall response of confirmed complete response (CR) or partial response (PR)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG fianlimab
- DRUG cemiplimab
Study Locations (20)
Florida
- Clermont Oncology Center - Clermont
- Miami Veterans Administration HealthCare System - Miami
- Mid Florida Hematology and Oncology Center - Orange City
- Pinellas Hematology and Oncology - St. Petersburg
- Tallahassee Memorial Healthcare - Tallahassee
- Moffitt Cancer Center - Tampa
Arizona
- Arizona Clinical Research Center - Tucson
- Yuma Regional Medical Center - Yuma
California
- Emad Ibrahim, MD, Inc. - Redlands
Connecticut
- Eastern CT Hematology and Oncology Associates - Norwich
Illinois
- University of Illinois - Chicago
Louisiana
- Mary Bird Perkins Cancer Center - Baton Rouge
Mississippi
- Hattiesburg Clinic - Hattiesburg
Missouri
- Mercy South - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 850 participants |
| Start Date | 2023-06-30 |
| Est. Completion | 2032-02-05 |
| Phase | Phase 2 |
What the registry record for NCT05785767 still lists
NCT05785767 is an interventional study that assigns participants to a tested intervention. The registered 850 participants enrollment target is mid-sized for trials with a published cap, above the 344-participant average among 22 other Advanced Non-Small-Cell Lung Cancer trials with a reported enrollment target (147% higher).
The record links to 1 condition, with Advanced Non-Small-Cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05785767 names 20 study sites across 14 states, led by Florida, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT05785767 about?
NCT05785767 is a clinical study titled "A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)". This study is researching an experimental drug called fianlimab (also called REGN3767), combined with a medication called cemiplimab (also called REGN2810), individually called a "study drug" or collectively called "study drugs". The study is focused on patients who have advanced non-small cell lung...
What is the current status of trial NCT05785767?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 850 participants. The study started on 2023-06-30. Estimated completion is 2032-02-05.
What conditions does trial NCT05785767 study?
This clinical trial studies the following conditions: Advanced Non-Small-Cell Lung Cancer.
What interventions are being tested in trial NCT05785767?
The interventions under investigation include: Placebo (DRUG), fianlimab (DRUG), cemiplimab (DRUG).
Who is sponsoring clinical trial NCT05785767?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05785767 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Non-Small-Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05785767's enrollment target sits among peer trials
850 3rd of 22 higher than 20 of 22 other Advanced Non-Small-Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Non-Small-Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
RECRUITING · Phase 2
-
Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG
RECRUITING · Phase 2
-
Study With Various Immunotherapy Treatments in Participants With Lung Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03507257 · 850 participants
Longitudinal Early-onset Alzheimer's Disease Study Protocol
- NCT05846841 · 850 participants · NA
Personalized Tobacco Treatment in Primary Care (MOTIVATE)
- NCT05987059 · 850 participants · Phase 2
Involving Communities in Addressing the Maternal Health Crisis: Making an IMPACT
- NCT06289673 · 850 participants · Phase 4
Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI